Compare Global X CleanTech (CTEC) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X CleanTech vs GSK plc — how do they compare? Global X CleanTech trades at $56.49, while GSK plc trades at $51.21 (market cap $101.55B). The key difference: GSK plc pays a 3.5% dividend while Global X CleanTech pays none, and GSK plc is trading nearer its 52-week high, Global X CleanTech nearer its low. Which is the better fit depends on your goals.
| CTEC | GSK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $61.18 |
52-Week Low | $39.45 | $36.20 |
Market Cap | — | $101.55B |
Enterprise Value | — | $122.16B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTEC trades at $57.34, down 2.88% today amid bearish technical signals, with moving averages indicating selling pressure but oscillators showing potential oversold conditions. Key financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental clarity. The company has announced a future dividend of $0.07 per share payable in July 2026, though recent earnings and cash flow data are not provided.
The outlook remains cautious due to weak technical momentum and incomplete financial disclosure. Investment opportunity hinges on upcoming financial results revealing profitability and growth, while risks include persistent selling pressure and lack of current fundamental visibility. Investors await clearer earnings updates to assess valuation and business health.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X CleanTech
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
